Barbara Pro

Columbia University Irving Medical Center — United States

Medicine · Health Sciences

62h-index17.1kcitations421works1.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(333), Chronic Lymphocytic Leukemia Research(113), Cutaneous lymphoproliferative disorders research(81), Viral-associated cancers and disorders(75), T-cell and Retrovirus Studies(73)

Publications419 total

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial - impact of prior therapy and expanded safety analysis
Blood·2025Open Access
Ruxolitinib increases immunogenicity and primes the tumor microenvironment for immune checkpoint blockade in 9p24.1 amplified lymphomas
Blood·2025Open Access
Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study
Blood·2025
333 Inverse Psoriasis-Like Mogamulizumab-Associated Rash in a Patient with Cutaneous T-cell Lymphoma
Journal of Investigative Dermatology·2025Open Access
329 Serum Proteomic Analysis Distinguishes Early Mycosis Fungoides from Atopic Dermatitis
Journal of Investigative Dermatology·2025Open Access
TCL-137: Duvelisib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results From the Phase 2 PRIMO Trial
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: TCL-137 Duvelisib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results From the Phase 2 PRIMO Trial
Clinical Lymphoma Myeloma & Leukemia·2025
Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia
Blood Neoplasia·2025· 1 citedOpen Access
Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents
Leukemia & lymphoma/Leukemia and lymphoma·2025
Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma
Leukemia & lymphoma/Leukemia and lymphoma·2025
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)
Hematological Oncology·2025Open Access
766 | OUTCOMES OF PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA BY RACE/ETHNICITY AND CLINICAL TRIAL ENROLLMENT
Hematological Oncology·2025· 1 citedOpen Access
419 | MULTICENTER REAL‐WORLD OUTCOMES IN DIFFUSE LARGE B‐CELL LYMPHOMA PROFILED WITH A COMMERCIALLY‐AVAILABLE CIRCULATING TUMOR DNA ASSAY
Hematological Oncology·2025Open Access
854 | SEQUENCING‐GUIDED CHEMOTHERAPY OPTIMIZATION USING REAL‐TIME EVALUATION IN NEWLY DIAGNOSED DLBCL WITH CIRCULATING TUMOR DNA: SHORTEN‐ctDNA
Hematological Oncology·2025Open Access
301 | SOCIOECONOMIC DISPARITIES, DISEASE BURDEN AND TREATMENT INTENSITY IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA TREATED AT AN URBAN ACADEMIC CANCER CENTER
Hematological Oncology·2025Open Access
Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma
Blood·2024
Health Disparities in Lived Experiences of Patients with Cutaneous T-Cell Lymphoma: An All of Us Database Analysis
Blood·2024
Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
Blood·2024· 2 citedOpen Access
Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas
Blood·2024· 1 citedOpen Access
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
Blood·2024· 10 citedOpen Access
page 1 of 21Next →

Frequent Co-authors

Anas Younes(19), Peter McLaughlin(18), Luis Fayad(18), Jorge Romaguera(17), Maria Alma Rodriguez(13), Felipe Samaniego(12), Fredrick B. Hagemeister(11), Ranjana H. Advani(10), Michelle A. Fanale(10), Andrei R. Shustov(10), André Goy(9), Nam H. Dang(8), Fernando Cabanillas(8), Chitra Hosing(8), Nancy L. Bartlett(7), Larry W. Kwak(7), Issa F. Khouri(7), Richard E. Champlin(7), Tim Illidge(6), Steven M. Horwitz(6)